For laboratory research purposes only. Not for human consumption. This article is general regulatory information, not legal advice; see the closing note.
“Are research peptides legal in Europe?” is one of the most common questions researchers ask before sourcing compounds for in-vitro and preclinical work, and it does not have a single clean answer. Europe is not one legal space: the European Union shares a common framework for what counts as a medicine, but each member state has its own implementing statutes, its own controlled-substances lists, and its own enforcement body, and non-EU states such as Switzerland and the post-Brexit United Kingdom run separate systems entirely. This guide explains the EU-wide framework that applies everywhere, gives verified detail for five jurisdictions, and shows you how to check the current status in your own country rather than relying on a one-size-fits-all claim.
A note on scope, stated up front because it matters: we deliberately do not publish a “legal status” verdict for all 27 EU member states. Statutes and controlled-substances lists change, national classifications differ in their detail, and a confident-looking table covering every country would inevitably contain errors. Where we can cite a primary source, we name it. Where we cannot, we tell you how to find the answer yourself.
The EU-Wide Framework: It Starts With the Definition of a “Medicine”
The single most important concept across the entire EU is how a substance becomes legally classified as a medicinal product. This is set by Directive 2001/83/EC, the Community code relating to medicinal products for human use, which every member state has transposed into national law.
Under Article 1(2) of the Directive, a substance is a medicinal product in either of two ways:
- By presentation: any substance “presented as having properties for treating or preventing disease in human beings.”
- By function: any substance that “may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.”
This two-limb test is the hinge on which research-chemical regulation turns. A synthetic peptide sold strictly as a research chemical, labelled “not for human consumption,” carrying no therapeutic claims, and intended for laboratory use, generally falls outside the presentation limb, because nothing about how it is presented suggests treatment of disease. That is precisely why research-only framing matters beyond marketing: a product marketed with disease claims or human-use instructions can be pulled into the medicinal-product definition by presentation alone, regardless of the molecule itself.
Two important caveats apply everywhere:
- The label is not an automatic exemption. Classification ultimately turns on presentation, composition, and intended use taken together. A “research use only” sticker does not override the substance’s actual characteristics, and a borderline product can still be assessed case-by-case by a national authority.
- The advertising rules are strict. Article 86 onward of the Directive governs the advertising of medicinal products, and Article 87 prohibits advertising a medicine that does not hold a marketing authorisation. This is the legal backbone behind the rule that research compounds must never be promoted with dosing, outcomes, or disease claims.
The GLP-1 exception: elevated scrutiny EU-wide
There is one class of compounds that warrants separate mention everywhere in Europe. Semaglutide, tirzepatide, and liraglutide are active substances in medicines that hold marketing authorisations across the EU and the UK. Because authorised medicines built on these substances already exist, anything that presents an unlicensed GLP-1 compound as an alternative to those medicines maps directly onto the medicinal-product definition and the advertising prohibition above. Regulators treat this class with markedly higher scrutiny than ordinary research chemicals, both as an advertising-compliance matter and as a customs and import matter, where shipments can be examined as potential unlicensed-medicine imports. For GLP-1-class compounds in particular, framing must stay strictly scientific and researchers should confirm import and handling requirements through their own institution.
Verified Jurisdiction Detail
The following five jurisdictions are covered because their framework can be tied to a primary source. Each entry names the governing statute and the competent authority. None of this is a statement that any particular transaction is lawful; it is a description of the regulatory structure.
Germany: Arzneimittelgesetz (AMG)
Germany transposes the EU framework through the Arzneimittelgesetz (AMG, the Medicinal Products Act). Its § 2(1) defines a medicinal product in terms that mirror the Directive: substances intended for curing, alleviating, or preventing disease, or for restoring, correcting, or modifying physiological functions. The competent authority is the BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, the Federal Institute for Drugs and Medical Devices). Controlled substances are governed separately under the Betäubungsmittelgesetz (BtMG, the Narcotics Act), and items falling under the BtMG face import restrictions. A peptide sold as a research chemical with no therapeutic presentation generally sits outside the AMG’s medicinal-product definition, but the classification is assessed on presentation and intended use, and Germany is a strong-enforcement jurisdiction, particularly for GLP-1-class compounds. Source: Medicinal Products Act (AMG), gesetze-im-internet.de; BfArM — Medicinal products.
Netherlands: Geneesmiddelenwet, Opiumwet, Warenwet
Dutch sourcing sits at the intersection of three laws. The Geneesmiddelenwet (Medicines Act) carries the medicinal-product definition and the medicines-advertising rules, enforced by the IGJ (Inspectie Gezondheidszorg en Jeugd) with the CBG-MEB as the licensing board. The Opiumwet (Opium Act) lists controlled substances on its List I and List II. The Warenwet (Commodities Act), enforced by the NVWA, is the framework that compliant research chemicals typically fall under: those that are neither medicines nor on the Opiumwet lists, and are sold with “not for human consumption” labelling. Standard research peptides are not on the Opiumwet lists as of mid-2026, but novel compounds should be checked against the current lists. For the full Dutch picture, see our dedicated Netherlands guide. Source: companion Netherlands guide (verified against KNMP, Douane Kennisbank, IGJ, CBG-MEB, business.gov.nl).
France: Code de la santé publique (ANSM)
France governs medicines through the Code de la santé publique (CSP). The medicinal-product definition sits at Article L.5111-1, mirroring the EU two-limb test. Controlled and poisonous substances are classified as stupéfiants (narcotics) under the arrêté du 22 février 1990 and as substances vénéneuses on Lists I and II under Article L.5132-6. The competent authority is the ANSM (Agence nationale de sécurité du médicament et des produits de santé), which since February 2022 also classifies controlled and poisonous substances. These lists are revised periodically by ANSM decision, so the current classification of any new or analogue compound should be confirmed before ordering. For the full French picture, see our dedicated France guide. Source: companion France guide (verified against ANSM, Legifrance).
United Kingdom: MHRA (post-Brexit)
Since leaving the EU, the UK runs its own regime, with the MHRA (Medicines and Healthcare products Regulatory Agency) as the competent authority. The UK retained an equivalent medicinal-product definition and the prohibition on advertising unlicensed medicines. Two points are specific to the UK research-peptide context. First, the GLP-1 medicines semaglutide, tirzepatide, and liraglutide are licensed in the UK but are prescription-only; supplying them outside authorised channels (for example as unlicensed weight-loss products or research chemicals for human use) is illegal, while compounds such as BPC-157 hold no UK marketing authorisation. Second, the MHRA has been visibly active in enforcement: it has reported seizing counterfeit GLP-1 pens (including fake semaglutide pens) and has shut down an illegal facility manufacturing unlicensed GLP-1 products. Post-Brexit, UK-bound shipments are also subject to import controls that EU-internal movements are not. The UK is therefore a notably elevated-enforcement environment for GLP-1-class compounds. Sources: GOV.UK — MHRA Drug Safety Update on GLP-1 receptor agonists; Pharmaceutical Technology — MHRA shuts down illegal GLP-1RA facility.
Switzerland: Swissmedic (non-EU)
Switzerland is outside the EU and runs an independent system under the Therapeutic Products Act (Heilmittelgesetz, HMG, also the TPA), administered by Swissmedic, the Swiss Agency for Therapeutic Products. Medicinal products may only be distributed in Switzerland if authorised by Swissmedic, and the Act also governs licensing for manufacturing and wholesale trade, market surveillance, and advertising. Because Switzerland sits outside the EU customs union, inbound shipments cross a customs border and are not EU-internal movements. Researchers ordering into Switzerland should treat the Swissmedic framework, not EU rules, as the governing reference and confirm import requirements before ordering. Source: Swissmedic — Swiss Agency for Therapeutic Products.
Every Other European Country: How to Check Your Own Jurisdiction
For the remaining EU member states and other European countries, we are not going to invent statute names, article numbers, agencies, or list classifications. Instead, here is a reliable method to establish the position in your own jurisdiction. The same EU framework above applies as a baseline in every EU member state; what differs is the national implementing statute, the controlled-substances list, and the enforcement body.
- Identify your national medicines authority. Every EU member state has one (the national counterpart to the bodies named above), plus the EMA at EU level. This authority publishes the national transposition of Directive 2001/83/EC and the medicines-advertising rules.
- Check your national controlled-substances list. Each country maintains its own narcotics/psychotropics schedule. Confirm whether the specific compound you intend to order appears on it, and re-check, because these lists are updated.
- Confirm the customs position for your country. Within the EU customs union, intra-EU movements are generally treated as internal-market shipments rather than imports; shipments arriving from outside the EU (or into non-EU states such as Switzerland and the UK) cross a customs border and can be examined. Customs treatment is separate from the advertising/classification question.
- Apply extra caution to GLP-1-class compounds. Wherever you are, semaglutide, tirzepatide, and liraglutide carry the elevated scrutiny described above.
- Ask your institution. University legal/compliance offices, research-procurement teams, and institutional safety officers can confirm the rules that apply to your specific setting, which is often the fastest authoritative answer.
When a source disagrees with a forum post or a vendor’s marketing copy, trust the primary source (the statute or the authority’s own website) over the secondary commentary.
What This Means for Sourcing Decisions
The regulatory picture has a few practical consequences that hold across Europe:
- Research-only framing is structural, not cosmetic. Because classification can turn on presentation, a supplier that markets compounds with disease claims, human dosing, or outcome promises raises the regulatory profile of the entire transaction. Suppliers that keep strictly to research framing and “not for human consumption” labelling are the appropriate starting point.
- EU-internal shipping avoids a customs border. Suppliers shipping from within the EU customs union move goods as internal-market shipments to other EU destinations, without the customs import formalities that apply to shipments arriving from outside the EU or into non-EU states, though restricted or unlawful goods can still be controlled.
- GLP-1-class compounds sit in a category of their own. Treat semaglutide, tirzepatide, and liraglutide as the highest-scrutiny class for both advertising compliance and customs.
- Documentation supports compliance. A clear Certificate of Analysis, research-use-only labelling, and a proper commercial invoice make the research nature of a purchase legible to an institution’s procurement and compliance records.
Summary
Europe shares a common foundation, the medicinal-product definition by presentation or function in Directive 2001/83/EC together with the prohibition on advertising unlicensed medicines, but the detail lives in national law. We have given verified, sourced detail for Germany (AMG, BfArM, BtMG), the Netherlands (Geneesmiddelenwet, Opiumwet, Warenwet), France (Code de la santé publique, ANSM), the UK (MHRA, post-Brexit, active GLP-1 enforcement), and Switzerland (Swissmedic, Therapeutic Products Act, non-EU). For every other country, the right move is to check your national medicines authority and controlled-substances list directly rather than rely on a blanket claim. And everywhere, GLP-1-class compounds warrant the most caution.
This is general regulatory information, not legal advice. Regulations and controlled-substances lists change, national rules differ in their detail, and individual circumstances vary. Before ordering, confirm the current position for your specific jurisdiction and use case with your institution’s compliance/legal office or with qualified local counsel.
CertaPeptides ships from within the EU, posts full third-party COA documents on every product page, and labels all compounds for research use only. No human-use claims are made.
This article is for research information purposes only. All compounds referenced are supplied exclusively as research chemicals for laboratory use, not as medicinal products, and are not intended for human or animal use. Some compounds named (for example semaglutide and tirzepatide) are active substances in separately authorised medicines; CertaPeptides supplies only research-grade chemicals and makes no therapeutic claims.